BeiGene
Total Listings
Open Positions
Flagged Listings
Trust Score
Director, Digital Solution Architecture
50Medium trust scoreSenior Director, Global Clinical Operations Franchise Head, Hematology
50Medium trust scoreDirector, Pricing & Contracting Strategy - Hematology
50Medium trust scoreHealthcare Solution Partner (Job Level: Associate Manager/Manager) - Gyeongsang
40Medium trust scoreDirector, Safety Scientist
50Medium trust scoreSenior Director / Executive Director, Hematology Marketing Brand Lead
50Medium trust score| Title | Location | Source | Score | Status |
|---|---|---|---|---|
| Director, Digital Solution Architecture | 🇺🇸 United States | himalayas | 50Medium trust score | OPEN |
| Senior Director, Global Clinical Operations Franchise Head, Hematology | 🇺🇸 United States | himalayas | 50Medium trust score | OPEN |
| Director, Pricing & Contracting Strategy - Hematology | 🇺🇸 United States | himalayas | 50Medium trust score | EXPIRED |
| Healthcare Solution Partner (Job Level: Associate Manager/Manager) - Gyeongsang | 🌍 South Korea | himalayas | 40Medium trust score | EXPIRED |
| Director, Safety Scientist | 🇺🇸 United States | himalayas | 50Medium trust score | EXPIRED |
| Senior Director / Executive Director, Hematology Marketing Brand Lead | 🇺🇸 United States | himalayas | 50Medium trust score | EXPIRED |
BeiGene is a global, commercial-stage biotechnology company dedicated to the discovery, development, manufacturing, and commercialization of innovative molecularly-targeted and immuno-oncology drugs for cancer treatment. While originating from China, the company maintains a significant global footprint, including substantial research, development, and commercial operations within the United States, positioning itself as a key player in the global oncology landscape. The company's core mission is to develop transformative medicines that address significant unmet medical needs for cancer patients worldwide. BeiGene has built a robust pipeline and successfully commercialized several key oncology products. Its flagship products include BRUKINSA (zanubrutinib), a BTK inhibitor approved for various B-cell malignancies, and TEVIMBRA (tislelizumab), a PD-1 inhibitor used in multiple cancer types. BeiGene leverages its integrated R&D capabilities to advance a diverse portfolio of investigational therapies across various stages of clinical development.
- Global biotechnology company with significant operations in the United States and China.
- Focused exclusively on oncology, developing both molecularly-targeted and immuno-oncology drugs.
- Listed on NASDAQ (BGNE) and the Hong Kong Stock Exchange.
- Has a rapidly expanding pipeline of investigational cancer therapies.
- Known for its integrated discovery, development, manufacturing, and commercialization capabilities.
Last researched: 3/28/2026
Think something looks wrong? Report an inaccuracy.